175 - Balancing Innovation and Safety (S12E10)

Okay, let's unpack this fundamental challenge
in drug development. It's this constant tension,
isn't it, between the urgent need for new medicines
and the absolute imperative to make sure they're
safe. It absolutely is. That's the core dilemma.
Yeah, it really makes you think, how do we push
progress faster, get those breakthroughs without,
you know, cutting corners on patient safety?
That's the tightrope walk. It's driven by huge
unmet medical needs, the competitive landscape
too, but safety, safety has to be paramount.
Every single step exactly and that's our deep
dive today this whole intricate balancing act
innovation Versus safety and bringing new drugs
for we've got some great sources pre -clinical
handbooks regulatory stuff like the CFR national
rule books and even some really specific examples
from Organic process research the real midi gritty.
So the mission here is to pull out the key insights
How was this balance actually managed to give
you a clear picture? But you know keep it engaging
avoid getting bogged down in jargon Ready? Absolutely.
Let's start with those driving forces. You mentioned
unmet needs. That's huge. Think about diseases
with few or no options. Right. The pressure is
immense. And the competition between research
groups, that fuels it too. Definitely. But running
right alongside that drive for speed is this
non -negotiable commitment to safety. It's not
just a box to tick for regulators. No, it feels
much more fundamental than that. It is. It starts
way before humans are involved. Preclinical investigations,
the lab work, in vitro and the animal studies,
in vivo. This is where you first look for trouble
signs. Exactly. Trying to figure out. potential
toxic effects? Which organs might be hit? How
does the dose affect things? Is it reversible?
It's so critical the FDA actually mandates it
in 21 CFR 312 .23A8. They need that non -clinical
data to feel confident it's reasonably safe for
that first human dose. So that specific rule
really underlines that you need solid pre -clinical
safety data before you can even think about human
trials. Precisely. It's an early warning system
trying to predict essentially. And I saw in the
anti -cancer drug development guide they use
very specific tumor models in animals for efficacy
tests things like pancreatic ductal adenocarcinomas,
colon adenocarcinoma. Yes, specific models often
chosen because they aren't easily rejected by
the animal's immune system or maybe they're resistant
to current drugs. It helps get a clearer signal
on whether the new drug actually has anti -cancer
potential. So it's about reliable indicators.
Right. consistency. And importantly, all this
preclinical data, especially the safety findings,
directly feeds into setting that initial dose
for human trials. How does that work exactly?
Well, we look for something called the NOAEL,
the No Observed Adverse Effect Level, basically
the highest dose in animal studies that didn't
cause significant problems. Then you apply safety
factors. You divide that NOAEL, often by quite
a bit, to get a much lower cautious starting
dose for humans. So find the animal limit, then
dial it way back for people. Sounds careful.
Very. It has to be. Because you're introducing
something completely new into a biological system,
there's always inherent risk uncertainty. Biology
isn't always perfectly predictable. No, definitely
not. Which is why development is so iterative.
Findings from one stage really dictate how you
design the next. If pre -clinical studies flag,
say, a potential liver issue. Then the clinical
trial protocol will specifically watch liver
function like a hawk in the human participates.
Exactly. It's a step -by -step process, building
evidence, always looking for issues. And you
mentioned predictive models earlier. It's not
just about watching animals, right? There's more
planning. Oh, absolutely. Preclinical study design
uses predictive models more and more to choose
the best animal models, the right dose ranges,
anticipate safety concerns. And in vitro models,
lab -based tests are key for understanding ADME,
Yeah. Absorption, distribution, metabolism, excretion.
Basically, how the drug gets in, where it goes,
how it's broken down, and how it gets out. Understanding
that early, like we talked about with quality
by design, is crucial for designing safer drugs.
Right. Which brings us neatly to the ethical
side of things. Yeah. It's not just science and
safety data, is it? Not at all. There's a huge
ethical dimension. balancing that speed versus
thoroughness, we can't rush things if risks aren't
fully understood. And in clinical trials, too.
Absolutely. How participants are recruited, informed
consent, constant monitoring of their well -being,
it's all governed by strict ethical principles.
And as we said, using more in vitro models also
helps ethically, potentially reducing animal
testing. It's a constant weighing of benefit
versus risk, guided by ethics. Okay, so this
whole complex process, it doesn't just... happen
in a vacuum. There are gatekeepers. Major ones.
Regulatory bodies like the FDA here in the US
or the EMA in Europe, they set the rules, enforce
the standards for safety and efficacy. They're
the critical checks and balances. The ultimate
decision makers, really. They see all the data
before anything gets approved. They do. A huge
step is submitting the IND, the Investigational
New Drug Application, or the IMPD in Europe.
That's the big package of information. It is.
It compiles everything. Pharmacology, toxicology
from those pre -clinical studies, chemistry details,
manufacturing clans, quality control, and the
detailed protocol for the first human trials.
It's the foundation. Wow. So you lay everything
out before even the first dose in a human trial
subject. That's intense vetting. It needs to
be. And even once trials start, the oversight
continues. To get marketing approval, companies
need substantial evidence, that's a legal term,
from adequate and well -controlled studies. That's
straight from regulations like 21 CF - adequate
and well controlled that means things like control
groups proper study design exactly minimizing
bias getting reliable data on benefits and risks
and everything has to follow GCP good clinical
practice you GCP yeah international ethical and
scientific quality standards think ICH E6 21
CFR 314 it covers participant rights safety data
integrity the whole works ensures the trial results
are credible and it's similar for medical devices
too under the CDR each branch of the FDA so pill
Devices, same high bar for safety and effectiveness.
Okay, let's make this more concrete. Can we look
at specific examples, challenges where this innovation
safety balance really plays out? Sure. Think
about nanotechnology in drug formulations. It's
innovative stuff, like using amorphous nanoparticles
to help drugs dissolve better, which can boost
absorption. Sounds good. Better drug delivery.
It can be. But the challenge, the safety aspect,
is stability. Are those tiny amorphous particles
going to stay stable during manufacturing on
the shelf, or could they change back to a less
soluble form that might reduce effectiveness,
maybe even change the safety profile? Ah, OK.
So the innovation creates a new potential. problem
to solve. Precisely. Researchers are looking
at things like nanoco crystals as potential solutions
to keep things stable. Another big area is understanding
ADME, what the body does to the drug. Absorption,
distribution, metabolism, excretion again. Right.
Things like lipophilicity, how fat -loving a
drug is affects how it moves through tissues.
Or interactions with transport proteins like
p -glycoprotein, these cellular gatekeepers.
These factors massively influence safety and
efficacy. They're like tracking the drug's entire
journey. Exactly. Is it metabolized too fast?
or into something toxic? Does it interfere with
other drugs? These are critical safety questions.
And even in making the drug itself, the chemistry,
I saw mentions in the OPRND literature about
impurities. Yes, that's a great example. One
OPRND article discussed making tosalamedoxam.
During the process, a potentially harmful impurity,
ethyltosolate, could form. Junotoxic, I think
it said, meaning it could potentially damage
DNA. Correct. So while purification steps like
crystallization remove most of it, the chemists
have to be aware, understand how it forms, and
develop ways to control it to incredibly low,
safe levels. Sometimes they even change the whole
process, like using citric acid as a catalyst
to avoid making it in the first place. So Sexy
drives the actual chemistry design. It's not
just about making the target molecule. Absolutely.
It's about the whole process and controlling
anything potentially harmful. What about really
early on, finding drug candidates in the first
place? High -throughput screening, HTS is key
there. Testing thousands, millions of compounds
quickly against a target. Finding initial hits.
Right. Then medicinal chemists take those hits
and start tweaking them. They want to improve
activity, make the drug more selective for its
target, but right away they're also thinking
safety. Does it hit other targets unintentionally?
That could cause side effects. So precision is
important from the start. Not just hitting the
target, but only the target. Ideally. Ideally,
yes. And then there's formulation. Turning the
drug substance into a usable medicine, a pill,
an injection. That has safety angles too. Definitely.
For inhaled drugs, getting a consistent dose
to the lungs is crucial for efficacy and avoiding
irritation. For injections, you need to adjust
things like osmolarity, pH, so it's compatible
with body fluids, doesn't cause pain or tissue
damage. These details matter hugely for patient
safety and tolerance. It really drives home that
safety isn't just one check. It's woven through
everything. from molecule design to the final
product. Now you mentioned quality by design,
QBD. earlier. How does that fit in? QBD is a
more systematic approach. It's about understanding
and controlling product quality, including safety
and efficacy attributes right from the beginning.
Building quality in, not just testing it at the
end. Exactly. You identify the critical quality
attributes early, the things essential for safety
and efficacy. You figure out what factors influence
them. Then you design the drug and the manufacturing
process to consistently hit those quality targets.
So it's more proactive based on understanding
the science and the process. Yes. It allows you
to anticipate and mitigate potential risks much
better. It can lead to more robust products and
potentially even smoother regulatory reviews
because you understand your product so deeply.
Sounds like a smarter, safer way to develop drugs.
Looking ahead now, the field's always changing.
New tech like AI, nanotech, how does that impact
this innovation safety balance? That's the big
question now. AI, for instance, has Amazing potential.
Identifying targets, predicting drug behavior,
optimizing trials. It could really speed things
up. Nanotech offers new delivery methods, but
these also bring new safety questions. How do
we evaluate the safety of AI -designed molecules?
What are the long -term effects of nanoparticles
in the body? Our evaluation methods need to evolve,
and the regulatory frameworks need to adapt,
too, to ensure these powerful tools are used
safely. So the promise is huge, but we need safety
science and regulation to keep pace. That balance
remains critical. Always. Innovation has to be
tied to a constantly evolving understanding of
safety. So wrapping up this deep dive, it really
comes back to that core tension, the push for
innovation, for answers to devastating diseases.
constantly balanced against the absolute need
for safety and efficacy. Yes, and we've seen
how that plays out everywhere. Preclinical toxicity
tests, ethical oversight and trials, regulatory
gatekeeping, careful manufacturing, smart formulation,
and newer approaches like QBD trying to build
safety in from the start. And it's crucial for
you listening to remember this whole complex,
often invisible process is directly linked to
the medicines available and, well, to your health.
It is. It's a massive undertaking driven by the
goal of improving health, but always, always
with safety as the anchor. On that note, here's
something to think about. As AI gets more integrated
into discovering and developing drugs, how might
that genuinely speed up innovation? But crucially,
how do we make sure those vital safety checks
aren't just maintained, but maybe even enhanced?
What new ethical questions, what new regulatory
hurdles might pop up as these powerful technologies
become more central to bringing treatments to
you? Definitely something to ponder that intersection
of cutting -edge tech and fundamental safety.